SCHEMBL15549396

SCHEMBL15549396

Nc1nc(CC2CCCCC2)cs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.46
HSD17B10 Q99714 2/20 0.43
GABRA5 P31644 1/20 0.43
GABRB2 P47870 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.41
NOS1 P29475 1/20 0.41
MAPT P10636 1/20 0.39
NMT2 O60551 1/20 0.39
NMT1 P30419 1/20 0.39
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 2/20 0.38
TSHR P16473 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
RAB9A P51151 5/20 0.37
NPC1 O15118 3/20 0.37
ATM Q13315 1/20 0.37
GAA P10253 2/20 0.37
ALOX15 P16050 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17709802 0.95 LMNA (0.47) LMNAHSD17B10GABRA5GABRB2SMN1; SMN2
SCHEMBL20000852 0.91 GABRA5 (0.47) LMNAHSD17B10GABRA5GABRB2SMN1; SMN2
SCHEMBL28160951 0.80 HTR6 (0.39) SMN1; SMN2ALDH1A1TSHRCNR1CNR2
SCHEMBL28161480 0.80 CNR1 (0.38) SMN1; SMN2ALDH1A1TSHRCNR1CNR2
SCHEMBL2820205 0.76 CNR1 (0.40) LMNASMN1; SMN2ALDH1A1CNR1CNR2
SCHEMBL25393216 0.76 EPHX2 (0.46) LMNAHSD17B10GABRA5GABRB2SMN1; SMN2
SCHEMBL15549157 0.76 HTR6 (0.39) SMN1; SMN2ALDH1A1KDM4ECNR1CNR2
SCHEMBL17709923 0.74 HTR6 (0.34) TSHRCNR1CNR2NPC1
SCHEMBL2819181 0.74 CNR1 (0.39) SMN1; SMN2TSHRCNR1CNR2RAB9A
SCHEMBL5240163 0.74 GABRA5 (0.50) LMNAHSD17B10GABRA5GABRB2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10301272-B2 Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] PHENEX PHARMACEUTICALS AG (DE) 2019-05-28 US disclosed
US-20150175562-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] PHENEX PHARMACEUTICALS AG (DE) 2015-06-25 US disclosed
EP-2855438-A2 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES Galleon Pharmaceuticals, Inc. (US) 2015-04-08 EP disclosed
EP-2855440-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] Phenex Pharmaceuticals AG (DE) 2015-04-08 EP disclosed
WO-2013178362-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] PHENEX PHARMACEUTICALS AG (DE) 2013-12-05 WO disclosed
WO-2013181217-A2 NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES GALLEON PHARMACEUTICALS, INC. (US) 2013-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175562-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] RORA, RORB, RORC LMNA 4271/4885HSD17B10 962/4885GABRA5 202/4885
US-10301272-B2 Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] RORA, RORB, RORC LMNA 4258/4885HSD17B10 884/4885GABRA5 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.